Decoding 6 Analyst Evaluations For Recursion Pharmaceuticals
Decoding 6 Analyst Evaluations For Recursion Pharmaceuticals
解析6個分析師對於Recursion Pharmaceuticals的評估
6 analysts have expressed a variety of opinions on Recursion Pharmaceuticals (NASDAQ:RXRX) over the past quarter, offering a diverse set of opinions from bullish to bearish.
過去一個季度，有6位分析師對Recursion Pharmaceuticals (NASDAQ:RXRX)發表了各種不同的意見，從看好到看淡不一而足。
The following table provides a quick overview of their recent ratings, highlighting the changing sentiments over the past 30 days and comparing them to the preceding months.
下表提供了他們最近的評級概況，突出了過去30天內情緒的變化，並將其與之前的月份進行了比較。
Analysts have recently evaluated Recursion Pharmaceuticals and provided 12-month price targets. The average target is $11.67, accompanied by a high estimate of $17.00 and a low estimate of $6.00. A decline of 15.62% from the prior average price target is evident in the current average.
Market Capitalization Analysis: Reflecting a smaller scale, the company's market capitalization is positioned below industry averages. This could be attributed to factors such as growth expectations or operational capacity.
Investigating Analyst Ratings: An Elaborate Study
分析師評級的調查：一項詳盡的研究
The...
淨...
登入免費觀看全文
登入/註冊